Literature DB >> 17569031

Carcinogenic susceptibility of rasH2 mice to troglitazone.

Meilan Jin1, Miwa Takahashi, Mitsuyoshi Moto, Masako Muguruma, Kazumi Ito, Kyoko Watanabe, Yusuke Kenmochi, Taichi Kono, Keiji Hasumi, Kunitoshi Mitsumori.   

Abstract

To evaluate the carcinogenicity of troglitazone in rasH2 mice, 7-week-old male and female rasH2 mice were fed a diet containing 0, 3,000 or 6,000 ppm troglitazone for 26 weeks. An increased tendency in the incidence of vascular tumors was observed in females of the 6,000 ppm group. The preliminary analysis using a high-density oligonucleotide microarray on a splenic hemangiosarcoma of a high dose female that could be obtained as a fresh sample showed that several genes related to the ras/MAPK pathway activation, angiogenesis, cell cycle and cell multiplication were up-regulated. In addition, most of the genes up-regulated were confirmed by the reverse transcriptase-polymerase chain reaction (RT-PCR). These results may suggest that the carcinogenic susceptibility of rasH2 mice to troglitazone is relatively low and up-regulations of the ras/MAPK pathway and angiogenesis-related genes are probably involved in the production of splenic hemangiosarcomas in rasH2 mice given troglitazone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569031     DOI: 10.1007/s00204-007-0218-1

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  2 in total

1.  Immunohistochemical detection of a potential molecular therapeutic target for canine hemangiosarcoma.

Authors:  Mami Adachi; Yuki Hoshino; Yusuke Izumi; Satoshi Takagi
Journal:  J Vet Med Sci       Date:  2015-12-21       Impact factor: 1.267

2.  Survey of tumorigenic sensitivity in 6-month rasH2-Tg mice studies compared with 2-year rodent assays.

Authors:  Shigeru Hisada; Kenjiro Tsubota; Kenji Inoue; Hisaharu Yamada; Takanori Ikeda; Frank D Sistare
Journal:  J Toxicol Pathol       Date:  2021-11-01       Impact factor: 1.628

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.